Artwork
iconShare
 
Manage episode 355247758 series 2933391
Content provided by SciPro. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by SciPro or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

A special series of Life Sci AI: The Podcast Series looking at AI in Drug Discovery begins with a fascinating episode featuring Dr David Wright, CTO and Co-Founder of Kuano. The discussion delved deep into the revolutionary role Kauno is playing in the Drug Discovery process.

Dr David Wright is the CTO and Co-Founder of Kuano, a startup whose mission is to use a unique combination of simulation and AI to bring quantum detail to drug design. By starting from an exquisitely detailed picture of enzyme mechanisms they are looking to create a new generation of therapeutics, whose current projects include creating novel anti-bowel cancer drugs.

Before co-founding Kuano, Dr Wright used simulation to understand how atomic details impact drug binding at UCL. His journey to Kuano involved collaborating in large international collaborative projects (CompbioMed, CCP-SAS, CHAIN, INSPIRE) that brought together experts from the supercomputing, academic and pharmaceuticals world to advance drug design. His multidisciplinary outlook is reflected in how Kuano is bringing a new perspective to structure-based drug design.

To speak to Nick, please drop an email to [email protected]

  continue reading

33 episodes